
TSE:MFC
This summary was created by AI, based on 27 opinions in the last 12 months.
Manulife Financial (MFC) is viewed positively by numerous analysts, with many highlighting its robust growth potential, especially in the Asian market and wealth management. The company has successfully increased its dividend yield, currently sitting at approximately 4-5%, while its price-to-earnings (PE) ratio remains attractive compared to peers in the banking sector. Analysts have noted concerns over potential earnings drops but maintain a long-term positive outlook, suggesting that MFC is suitable for income-focused investors. While many emphasize the reliability of MFC's dividend and its strong position in life insurance, there are mixed feelings regarding its growth prospects compared to other financial institutions. Overall, the sentiment leans towards MFC being a solid choice for those seeking steady income and moderate growth, but some experts advise caution regarding market volatility.
Fundamentals are wonderful, great dividend. But stock hasn’t done much for last 2 years. Lot of trading at $24. Wouldn’t touch it, unless for the dividend. It’s liabilities are concerning. Strong support at $23.40, get out if goes below $23. Can’t call a trend until hits $25. The good story is irrelevant if the stock is not performing.
It's been lagging its peers, largely because of new management since last fall. New management is putting more pressure of their troubled legacy businesses, namely long-term care in the U.S. They've been expanding aggressively in Asia. More importantly, they're looking at their cost-structure. They're aiming for an efficiency ratio under 50% by 2022, and currently at 55%. This means several billions in cost savings. Alaos, capital will be released from dispositions in the next few years. New management is modernizing this company. There could be some short-term pain, including write-offs, but current prices amount to exceptional value. (Analysts' price target: $29.46)
He sees $22.50 as key support. He wonders if there is topping action on the chart. He prefers Fairfax Financial, although it does not quite the same quality. MFC-T has been focused on their market, but prefers Sunlife (SLF-T), which is demonstrating better technical trending. He would suggest swapping MFC-T for SLF-T at current levels.
Since the Financial Crisis it has been a frustrating stock. The company has upside potential with the exposure in Asia and wealth management. Maybe with the new leadership it could break out and over to the new level releasing some capital. He still has faith in the longer term in the name, but it could be frustrating in the short term. (Analysts’ price target is $29.00)
They gave a lot of clarity on their legacy products at their Investor Day last week. They are expanding other parts of the business to drive down the impact of legacy businesses on their overall income. Their new CEO used to run Manulife Asia, which is very high growth. Their PE multiple of 9x is very low compared to Sun Life’s 12x. Their target ROE is 13% and they achieved that in the first quarter. The company’s Price to Earnings and Price to Book will rise if ROE stays this high. (Analysts’ price target is $29.65)
He owns no insurance companies. This one has had issues amongst the bunch with their acquisition of Hancock. They inherited the issue of long term care. It has unlimited liability potential. It is the cheapest and highest grower of the insurance companies and they have the Asia division growing quickly. This could be a unique asset. This is the torquey name to own. He is interest in it. 3.5% dividend. He is looking at it.
Manulife (MFC-T) versus Sunlife (SLF-T). He owned Manulife going into the financial crisis, but became concerned about management and sold out of their holdings. When Sunlife began to fall in sympathy they bought them – focusing on the preferred shares in particular. Manulife still has some questionable assets in the US and may not know how to offload them.
It is relatively out of favour but capital markets and interest rates are good. It is a growth story with a lot of negatives already priced in. (Analysts’ target: $29.21).